MEDICINOVA INC (MNOV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.63+0.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MNOV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Control operating expenses while managing an anticipated 18% increase in expenses for fiscal year 2026 compared to 2025.
Newly stated in 2026-Q1. Management guided operating expenses of approximately $16.2 million for fiscal year 2026, an 18% increase over 2025. Financials show ongoing operating losses each quarter with operating income negative from -$3.38M in 2025-Q3 to -$2.54M in 2026-Q2, indicating continued expense management challenges consistent with the guidance.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“the Company anticipates operating expenses of approximately $16.2 million for the fiscal year ending December 31, 2026, representing an increase of 18% compared with 2025.”
Focus on growing revenue through clinical trials and development programs, as reflected in sequential quarterly revenue increases.
Stated in 4 of last 4 quarters. Revenue grew from $123K in 2025-Q3 to $458K in 2026-Q2, reflecting progress in clinical and development activities. The trajectory shows delivering growth, though absolute revenue remains modest relative to operating losses.
“Revenue was $458,439 in 2026-Q2, up from prior quarters.”
“Revenue increased to $186,984 in 2026-Q1 from prior quarters.”
“Revenue was $123,319 in 2025-Q3, showing growth from 2025-Q2.”
“Revenue was $134,599 in 2025-Q2, a baseline for growth measurement.”
Continue efforts to reduce operating losses while advancing clinical programs and managing expenses.
Stated in 5 of last 5 quarters. Operating losses improved from -$3.61M in 2025-Q2 to -$2.54M in 2026-Q2, indicating progress in loss reduction. The trajectory is delivering moderate improvement consistent with management focus.
“Operating income was -$2.54M in 2026-Q2, improved from prior quarters.”
“Operating income was -$2.84M in 2026-Q1, better than earlier quarters.”
“Operating income was -$3.09M in 2025-Q4, showing ongoing losses.”
“Operating income was -$3.38M in 2025-Q3, reflecting loss challenges.”
“Operating income was -$3.61M in 2025-Q2, the highest loss in recent quarters.”
Over the trailing year it converted -1.69x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates (low R² over the window).
4 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.